(Q36989900)

17 August 2017

1 reference

title

Monoclonal antibodies for prophylaxis and therapy of infectious diseases (English)

1 reference

17 August 2017

1 reference

Jan ter Meulen

1

1 reference

PubMed ID

17979597

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Emerging Drugs

17 August 2017

1 reference

17 August 2017

12

1 reference

17 August 2017

4

1 reference

17 August 2017

525-540

1 reference

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Why is big Pharma getting out of antibacterial drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Passive antibody therapy for infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Passive immunity in prevention and treatment of infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Upping the ante on antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Infectious disease hospitalizations among older adults in the United States from 1990 through 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

The impact of hospital-acquired bloodstream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Treatment options for multidrug-resistant bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Resistance to antibiotics: are we in the post-antibiotic era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Prevention and management of cytomegalovirus infection in solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Management of recurrent hepatitis C in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Current status of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Respiratory syncytial virus infection in elderly and high-risk adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Current and future trends in the prevention, treatment and control of rabies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Role of natural and immune IgM antibodies in immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

How antibodies act as natural adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Immunity to fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Neutralization of animal virus infectivity by antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Targeting host cells harbouring viruses with radiolabeled antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Manufacture of recombinant polyclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Identification of ABC transporters in vancomycin-resistant Enterococcus faecium as potential targets for antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Antibody-based inhibitors of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Regulatory challenges: lessons from recent West Nile virus trials in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Cutting edge: Antigen is not required for the activation and maintenance of virus-specific memory CD8+ T cells in the lung airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Palivizumab in the prophylaxis of respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Engineered antibody fragments and the rise of single domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.4.525

10.1517/14728214.12.4.525

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17979597